Table 1.
Primary tumour characteristics
| n (%) | |
| Tumour size | |
| T1 | 20 (32.8) |
| T2 | 33 (54.1) |
| T3 | 7 (11.5) |
| T4 | 1 (1.6) |
| Nodal status | |
| N0 | 16 (26.2) |
| N1 | 22 (36.1) |
| N2 | 15 (24.6) |
| N3 | 8 (13.1) |
| Histopathology | |
| Ductal | 47 (77.0) |
| Lobular | 11 (18.0) |
| Other | 3 (4.9) |
| Histopathological grade | |
| Grade 1 | 0 (0) |
| Grade 2 | 25 (41.0) |
| Grade 3 | 34 (55.7) |
| Unknown | 2 (3.3) |
| ER expression | |
| Negative (0%) | 14 (23.0) |
| Weak (1%–9%) | 2 (3.3) |
| Moderate (10%–59%) | 6 (9.8) |
| High (>59%) | 39 (63.9) |
| PR expression | |
| Negative (0%) | 22 (36.1) |
| Weak (1%–9%) | 5 (8.2) |
| Moderate (10%–59%) | 5 (8.2) |
| High (>59%) | 29 (47.5) |
| HER2 status | |
| HER2-negative | 52 (85.2) |
| HER2-positive (CISH) | 9 (14.8) |
| Ki-67 expression | |
| Negative (<5%) | 2 (3.3) |
| Weak (5%–14%) | 15 (24.6) |
| Moderate (15%–30%) | 20 (32.8) |
| High (>30%) | 24 (39.3) |
| Focality | |
| Unifocal | 50 (82.1) |
| Multifocal | 11 (18.0) |
| Subtype | |
| Luminal A-like | 13 (21.3) |
| Luminal B-like (HER2-negative) | 29 (47.5) |
| Luminal B-like (HER2-positive) | 5 (8.2) |
| HER2-positive, non-luminal | 3 (4.9) |
| Triple-negative | 10 (16.4) |
| Unknown | 1 (1.6) |
| The first site of the distant metastasis | |
| Bone only | 17 (27.9) |
| Lung only | 9 (14.8) |
| Liver only | 5 (8.2) |
| Other | 6 (9.6) |
| Multiple sites | 24 (39.3) |
CISH, chromogenic in situ hybridisation; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.